Thesis Recap
Channel-pullback targets a classic mean-reversion entry within a momentum context: wait for a confirmed uptrend, buy when price pulls back to the lower regression channel or volume support, and exit at the upper channel or a defined resistance level. The universe spans 24 large-cap U.S. equities across tech, financials, healthcare, consumer, and energy — names with sufficient liquidity to make regression-channel signals reliable.
Backtest Snapshot
Over 451 days and 137 trades, the strategy produced a 7.62% total return (4.19% CAGR) on a notional $10,000 account, ending at $10,761.52. Those headline numbers carry significant caveats:
| Metric | Value |
|---|---|
| Total Return | 7.62% |
| CAGR | 4.19% |
| Sharpe Ratio | 0.40 |
| Max Drawdown | 14.83% |
| Win Rate | 39.39% |
| Trades | 137 |
| Turnover | 2,311% |
A Sharpe of 0.40 is below the conventional 0.5 threshold for a strategy worth scaling, and the 14.83% max drawdown is sizable relative to returns. The win rate of 39% is not a red flag on its own — trend-following and channel strategies can be profitable with sub-50% win rates if the reward-to-risk is favorable — but it does mean the strategy needs its winners to carry meaningful upside to stay in the black.
Turnover at 2,311% is notably high. At $1 per trade in fees (as modeled), the $137 total cost is modest, but real-world slippage on 137 fills across mid- to large-cap names could erode the thin margin further.
Walk-Forward Validation: A Cautionary Signal
The four-fold Walk-Forward Validation is where the picture gets complicated. Validation did not pass.
| Fold | Period | Return | Sharpe | Max DD |
|---|---|---|---|---|
| 1 | Aug 2024 – Jan 2025 | +6.53% | 1.25 | 6.16% |
| 2 | Jan 2025 – Jul 2025 | −11.42% | −1.70 | 16.09% |
| 3 | Jul 2025 – Dec 2025 | +20.68% | 3.86 | 3.26% |
| 4 | Dec 2025 – May 2026 | +3.63% | 0.74 | 8.44% |
Three of four folds were positive — that's an encouraging base rate. But Fold 2's −11.42% and a −1.70 Sharpe represent a genuine stress event, not noise. The PSR (Probabilistic Sharpe Ratio) of 0.702 suggests roughly 70% confidence the true Sharpe exceeds a benchmark — acceptable but not compelling. The DSR (Deflated Sharpe Ratio) of 0.196 adjusts for the seven parameter trials run during development, and its low value is a standard overfitting warning: the observed Sharpe may not survive out-of-sample over a longer horizon.
The out-of-sample return of 3.63% (Fold 4, the most recent period) is the number to watch — it's the closest proxy for live performance, and a 0.74 Sharpe there is the best single-fold result after the brutal Fold 2.
Recent Activity
The strategy has been notably disciplined in early July. Five of the last six scheduled runs executed zero trades, with one candidate rejected each time — suggesting the system found near-misses but held the filter.
The one active session was July 1, when the strategy bought 19 shares of DIS at $96.32 and sold 7 shares of WMT at $108.53. Portfolio value at that point stood at $10,106. As of July 6 the account has drifted up to $10,316, with $770.62 sitting in cash.
Looking back further, the strategy caught a tidy round-trip in CAT (bought at $857.78 on June 10, sold at $912.06 two days later) and cycled through DIS and MSFT positions — broadly consistent with the channel-entry thesis.
Strengths and Risks
Strengths: The thesis is sound and well-studied. Three of four walk-forward folds were profitable. The most recent out-of-sample fold shows improving risk-adjusted performance, and the strategy's selectivity — rejecting low-conviction setups — keeps turnover from spiraling.
Risks: Fold 2's drawdown exposed vulnerability in trending-but-choppy regimes, where pullbacks overshoot the lower channel before recovering. The low DSR is a quantitative flag that parameter choices may have been tuned to historical data. A 39% win rate with a 14.83% max drawdown demands disciplined position sizing in live deployment.
Bottom line: Channel-pullback is a live strategy in observation mode. The validation failure is not disqualifying — it's a prompt to watch Fold 4's out-of-sample trajectory closely over the next quarter before considering any increase in allocation.